|
| Status |
Public on Apr 21, 2021 |
| Title |
Divergent resistance mechanisms to HER2-targeted therapies in breast cancer (scRNA-Seq) |
| Organisms |
Homo sapiens; Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Divergent resistance mechanisms to HER2-targeted therapies in breast cancer
|
| |
|
| Overall design |
scRNA-Seq of two HER2+ PDX models treated with chemotherapy or HER2-targeting agents
|
| |
|
| Contributor(s) |
Janiszewska M, Stein S, Michor F, Polyak K |
| Citation(s) |
33886505 |
| |
| Submission date |
Nov 13, 2020 |
| Last update date |
Jul 20, 2021 |
| Contact name |
Kornelia Polyak |
| E-mail(s) |
[email protected]
|
| Phone |
617-632-2106
|
| Organization name |
Dana-Farber Cancer Institute
|
| Department |
Medical Oncology
|
| Lab |
Polyak
|
| Street address |
450 Brookline Ave
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02215 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL19415 |
Illumina NextSeq 500 (Homo sapiens; Mus musculus) |
|
| Samples (4)
|
|
| This SubSeries is part of SuperSeries: |
| GSE161423 |
Divergent resistance mechanisms to HER2-targeted therapies in breast cancer |
|
| Relations |
| BioProject |
PRJNA678283 |
| SRA |
SRP292491 |
Less...
More...